BiotechTube
AlivaMab Biologics

AlivaMab Biologics

San Diego, United States· Est.
alivamab.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

AlivaMab Biologics is a private, pre-revenue biotechnology services company specializing in antibody discovery and engineering. Its core asset is the proprietary AlivaMab Mouse platform, a transgenic system designed to generate high-quality, human antibody leads with improved developability profiles. The company operates a partnership-driven business model, offering end-to-end discovery services to biopharmaceutical clients, leveraging a seasoned leadership team with a proven track record in creating successful antibody drug discovery platforms.

AntibodiesBiologics

Technology Platform

Proprietary antibody discovery platforms including the AlivaMab Mouse (transgenic human antibody-producing mouse), AMMPD immunizations, fit-for-purpose screening, immune repertoire display, and bispecific format engineering.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

The large and growing therapeutic antibody market creates sustained demand for efficient discovery services.
The company's platform pedigree and focus on developability can differentiate it in a crowded CRO landscape.
Expansion into next-generation antibody formats (bispecifics, etc.) represents a significant growth avenue.

Risk Factors

Revenue is dependent on securing a limited number of large biopharma partnerships, creating client concentration risk.
The antibody discovery services sector is highly competitive with many established players.
Ultimate platform validation depends on partners successfully advancing candidates to approval, a long and uncertain process.

Competitive Landscape

AlivaMab competes in the crowded antibody discovery services market against large CROs (Charles River, Lonza), specialized platform companies (Ligand via OmniAb, BioNTech's Trillium), and internal R&D at large pharma. Its key differentiator is the proven track record of its leadership and the AlivaMab Mouse technology lineage.

More companies in Biologics / Biosimilars →More companies in United States →